Skip to main content
NCBI home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2003 Feb;79(1):45–52. doi: 10.1136/sti.79.1.45

Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2

D Fisman 1, E Hook 1, S Goldie 1
PMCID: PMC1744602  PMID: 12576614

Abstract

Objectives: Herpes simplex virus type 2 (HSV-2) is the most common cause of ulcerative genital disease in the United States, but infection is commonly unrecognised. Serological screening tests could identify discordantly infected couples and permit targeted interventions to limit HSV-2 transmission. Our objective was to evaluate the projected cost effectiveness of strategies to prevent HSV-2 transmission in couples with no history of HSV-2 infection.

Methods: We created a mathematical model to simulate the natural history and costs of HSV-2 transmission, and the expected impact of HSV-2 prevention strategies in monogamous, heterosexual couples. Strategies evaluated included (i) no screening; (ii) universal condom use; and (iii) serological screening for HSV-2 with condom use targeted to discordant couples. Screening tests considered included western blot (WB), ELISA, and ELISA with confirmation of positive test results using WB (ELISA→WB).

Results: Compared to no screening, the use of ELISA→WB prevented 38 future infections per 1000 couples, with a cost effectiveness ratio of $8200 per infection averted. The use of WB in all couples had an incremental cost effectiveness ratio of $63 600 per infection averted. Strategies of ELISA alone and universal condom use were not cost effective. The cost effectiveness of ELISA→WB improved with increasing prevalence of HSV-2, but worsened with decreasing condom compliance. Screening with ELISA alone was a reasonable strategy only when ELISA specificity increased to 99%.

Conclusions: Serological screening for unrecognised HSV-2 infection in monogamous, heterosexual couples is expected to decrease the incidence of HSV-2 infection, but increase healthcare costs. For couples choosing to be screened, a two step testing strategy (ELISA→WB) is recommended. Recommendations for a national policy to conduct serological screening will depend on the value placed on averting an incident HSV-2 infection.

Full Text

The Full Text of this article is available as a PDF (196.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashley R. L., Militoni J., Lee F., Nahmias A., Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988 Apr;26(4):662–667. doi: 10.1128/jcm.26.4.662-667.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ashley R. L., Wald A., Eagleton M. Premarket evaluation of the POCkit HSV-2 type-specific serologic test in culture-documented cases of genital herpes simplex virus type 2 [see comment]. Sex Transm Dis. 2000 May;27(5):266–269. doi: 10.1097/00007435-200005000-00005. [DOI] [PubMed] [Google Scholar]
  3. Ashley R. L., Wu L., Pickering J. W., Tu M. C., Schnorenberg L. Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol. 1998 Jan;36(1):294–295. doi: 10.1128/jcm.36.1.294-295.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Benedetti J. K., Zeh J., Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med. 1999 Jul 6;131(1):14–20. doi: 10.7326/0003-4819-131-1-199907060-00004. [DOI] [PubMed] [Google Scholar]
  5. Benedetti J., Corey L., Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994 Dec 1;121(11):847–854. doi: 10.7326/0003-4819-121-11-199412010-00004. [DOI] [PubMed] [Google Scholar]
  6. Brown Z. A., Benedetti J., Ashley R., Burchett S., Selke S., Berry S., Vontver L. A., Corey L. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991 May 2;324(18):1247–1252. doi: 10.1056/NEJM199105023241804. [DOI] [PubMed] [Google Scholar]
  7. Brown Z. A., Selke S., Zeh J., Kopelman J., Maslow A., Ashley R. L., Watts D. H., Berry S., Herd M., Corey L. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997 Aug 21;337(8):509–515. doi: 10.1056/NEJM199708213370801. [DOI] [PubMed] [Google Scholar]
  8. Bryson Y. J., Dillon M., Lovett M., Acuna G., Taylor S., Cherry J. D., Johnson B. L., Wiesmeier E., Growdon W., Creagh-Kirk T. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983 Apr 21;308(16):916–921. doi: 10.1056/NEJM198304213081602. [DOI] [PubMed] [Google Scholar]
  9. Bryson Y., Dillon M., Bernstein D. I., Radolf J., Zakowski P., Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis. 1993 Apr;167(4):942–946. doi: 10.1093/infdis/167.4.942. [DOI] [PubMed] [Google Scholar]
  10. Cates Willard., Jr The condom forgiveness factor: the positive spin. Sex Transm Dis. 2002 Jun;29(6):350–352. doi: 10.1097/00007435-200206000-00007. [DOI] [PubMed] [Google Scholar]
  11. Corey L., Adams H. G., Brown Z. A., Holmes K. K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983 Jun;98(6):958–972. doi: 10.7326/0003-4819-98-6-958. [DOI] [PubMed] [Google Scholar]
  12. Corey L., Fife K. H., Benedetti J. K., Winter C. A., Fahnlander A., Connor J. D., Hintz M. A., Holmes K. K. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med. 1983 Jun;98(6):914–921. doi: 10.7326/0003-4819-98-6-914. [DOI] [PubMed] [Google Scholar]
  13. Diamond C., Selke S., Ashley R., Benedetti J., Corey L. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sex Transm Dis. 1999 Apr;26(4):221–225. doi: 10.1097/00007435-199904000-00007. [DOI] [PubMed] [Google Scholar]
  14. Fleming D. T., McQuillan G. M., Johnson R. E., Nahmias A. J., Aral S. O., Lee F. K., St Louis M. E. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997 Oct 16;337(16):1105–1111. doi: 10.1056/NEJM199710163371601. [DOI] [PubMed] [Google Scholar]
  15. Hirth R. A., Chernew M. E., Miller E., Fendrick A. M., Weissert W. G. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000 Jul-Sep;20(3):332–342. doi: 10.1177/0272989X0002000310. [DOI] [PubMed] [Google Scholar]
  16. Ho D. W., Field P. R., Irving W. L., Packham D. R., Cunningham A. L. Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. J Clin Microbiol. 1993 Dec;31(12):3157–3164. doi: 10.1128/jcm.31.12.3157-3164.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Holmes A. M. Measurement of short term health effects in economic evaluations. Pharmacoeconomics. 1998 Feb;13(2):171–174. doi: 10.2165/00019053-199813020-00001. [DOI] [PubMed] [Google Scholar]
  18. Johannesson M., Pliskin J. S., Weinstein M. C. Are healthy-years equivalents an improvement over quality-adjusted life years? Med Decis Making. 1993 Oct-Dec;13(4):281–286. doi: 10.1177/0272989X9301300403. [DOI] [PubMed] [Google Scholar]
  19. Johnson R. E., Nahmias A. J., Magder L. S., Lee F. K., Brooks C. A., Snowden C. B. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med. 1989 Jul 6;321(1):7–12. doi: 10.1056/NEJM198907063210102. [DOI] [PubMed] [Google Scholar]
  20. Lahat E., Barr J., Barkai G., Paret G., Brand N., Barzilai A. Long term neurological outcome of herpes encephalitis. Arch Dis Child. 1999 Jan;80(1):69–71. doi: 10.1136/adc.80.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Langenberg A. G., Corey L., Ashley R. L., Leong W. P., Straus S. E. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med. 1999 Nov 4;341(19):1432–1438. doi: 10.1056/NEJM199911043411904. [DOI] [PubMed] [Google Scholar]
  22. Langenberg A., Benedetti J., Jenkins J., Ashley R., Winter C., Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med. 1989 Jun 1;110(11):882–887. doi: 10.7326/0003-4819-110-11-882. [DOI] [PubMed] [Google Scholar]
  23. Mertz G. J., Benedetti J., Ashley R., Selke S. A., Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992 Feb 1;116(3):197–202. doi: 10.7326/0003-4819-116-3-197. [DOI] [PubMed] [Google Scholar]
  24. Mertz G. J., Coombs R. W., Ashley R., Jourden J., Remington M., Winter C., Fahnlander A., Guinan M., Ducey H., Corey L. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis. 1988 Jun;157(6):1169–1177. doi: 10.1093/infdis/157.6.1169. [DOI] [PubMed] [Google Scholar]
  25. Mertz G. J., Critchlow C. W., Benedetti J., Reichman R. C., Dolin R., Connor J., Redfield D. C., Savoia M. C., Richman D. D., Tyrrell D. L. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA. 1984 Sep 7;252(9):1147–1151. [PubMed] [Google Scholar]
  26. Nilsen A. E., Aasen T., Halsos A. M., Kinge B. R., Tjøtta E. A., Wikström K., Fiddian A. P. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982 Sep 11;2(8298):571–573. doi: 10.1016/s0140-6736(82)90658-4. [DOI] [PubMed] [Google Scholar]
  27. Prober C. G., Corey L., Brown Z. A., Hensleigh P. A., Frenkel L. M., Bryson Y. J., Whitley R. J., Arvin A. M. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis. 1992 Dec;15(6):1031–1038. doi: 10.1093/clind/15.6.1031. [DOI] [PubMed] [Google Scholar]
  28. Prober C. G., Sullender W. M., Yasukawa L. L., Au D. S., Yeager A. S., Arvin A. M. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med. 1987 Jan 29;316(5):240–244. doi: 10.1056/NEJM198701293160503. [DOI] [PubMed] [Google Scholar]
  29. Randolph A. G., Hartshorn R. M., Washington A. E. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol. 1996 Oct;88(4 Pt 1):603–610. doi: 10.1016/0029-7844(96)00261-x. [DOI] [PubMed] [Google Scholar]
  30. Randolph A. G., Washington A. E., Prober C. G. Cesarean delivery for women presenting with genital herpes lesions. Efficacy, risks, and costs. JAMA. 1993 Jul 7;270(1):77–82. [PubMed] [Google Scholar]
  31. Reichman R. C., Badger G. J., Mertz G. J., Corey L., Richman D. D., Connor J. D., Redfield D., Savoia M. C., Oxman M. N., Bryson Y. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA. 1984 Apr 27;251(16):2103–2107. [PubMed] [Google Scholar]
  32. Sacks S. L., Aoki F. Y., Diaz-Mitoma F., Sellors J., Shafran S. D. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA. 1996 Jul 3;276(1):44–49. [PubMed] [Google Scholar]
  33. Schacker T., Hu H. L., Koelle D. M., Zeh J., Saltzman R., Boon R., Shaughnessy M., Barnum G., Corey L. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med. 1998 Jan 1;128(1):21–28. doi: 10.7326/0003-4819-128-1-199801010-00004. [DOI] [PubMed] [Google Scholar]
  34. Schmid D. S., Brown D. R., Nisenbaum R., Burke R. L., Alexander D., Ashley R., Pellett P. E., Reeves W. C. Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. J Clin Microbiol. 1999 Feb;37(2):376–379. doi: 10.1128/jcm.37.2.376-379.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Smith A., Denham I., Keogh L., Jacobs D., McHarg V., Marceglia A., Wood V. Psychosocial impact of type-specific herpes simplex serological testing on asymptomatic sexual health clinic attendees. Int J STD AIDS. 2000 Jan;11(1):15–20. doi: 10.1258/0956462001914841. [DOI] [PubMed] [Google Scholar]
  36. Sonnenberg F. A., Beck J. R. Markov models in medical decision making: a practical guide. Med Decis Making. 1993 Oct-Dec;13(4):322–338. doi: 10.1177/0272989X9301300409. [DOI] [PubMed] [Google Scholar]
  37. Spruance S. L., Tyring S. K., DeGregorio B., Miller C., Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996 Aug 12;156(15):1729–1735. [PubMed] [Google Scholar]
  38. Straus S. E., Seidlin M., Takiff H. E., Rooney J. F., Felser J. M., Smith H. A., Roane P., Johnson F., Hallahan C., Ostrove J. M. Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpes. Sex Transm Dis. 1989 Apr-Jun;16(2):107–113. doi: 10.1097/00007435-198904000-00013. [DOI] [PubMed] [Google Scholar]
  39. Tao G., Kassler W. J., Rein D. B. Medical care expenditures for genital herpes in the United States. Sex Transm Dis. 2000 Jan;27(1):32–38. doi: 10.1097/00007435-200001000-00007. [DOI] [PubMed] [Google Scholar]
  40. Waitzman N. J., Romano P. S., Scheffler R. M. Estimates of the economic costs of birth defects. Inquiry. 1994 Summer;31(2):188–205. [PubMed] [Google Scholar]
  41. Wald A., Benedetti J., Davis G., Remington M., Winter C., Corey L. A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections. Antimicrob Agents Chemother. 1994 Feb;38(2):174–176. doi: 10.1128/aac.38.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Wald A., Corey L., Cone R., Hobson A., Davis G., Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest. 1997 Mar 1;99(5):1092–1097. doi: 10.1172/JCI119237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wald A., Langenberg A. G., Link K., Izu A. E., Ashley R., Warren T., Tyring S., Douglas J. M., Jr, Corey L. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA. 2001 Jun 27;285(24):3100–3106. doi: 10.1001/jama.285.24.3100. [DOI] [PubMed] [Google Scholar]
  44. Wald A., Zeh J., Barnum G., Davis L. G., Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8–15. doi: 10.7326/0003-4819-124-1_part_1-199601010-00002. [DOI] [PubMed] [Google Scholar]
  45. Wald A., Zeh J., Selke S., Ashley R. L., Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995 Sep 21;333(12):770–775. doi: 10.1056/NEJM199509213331205. [DOI] [PubMed] [Google Scholar]
  46. Wald A., Zeh J., Selke S., Warren T., Ryncarz A. J., Ashley R., Krieger J. N., Corey L. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000 Mar 23;342(12):844–850. doi: 10.1056/NEJM200003233421203. [DOI] [PubMed] [Google Scholar]
  47. Wald Anna, Link Katherine. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2001 Dec 14;185(1):45–52. doi: 10.1086/338231. [DOI] [PubMed] [Google Scholar]
  48. Weinstein M. C., Siegel J. E., Gold M. R., Kamlet M. S., Russell L. B. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996 Oct 16;276(15):1253–1258. [PubMed] [Google Scholar]
  49. Whitley R., Arvin A., Prober C., Burchett S., Corey L., Powell D., Plotkin S., Starr S., Alford C., Connor J. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14;324(7):444–449. doi: 10.1056/NEJM199102143240703. [DOI] [PubMed] [Google Scholar]
  50. Whitley R., Arvin A., Prober C., Corey L., Burchett S., Plotkin S., Starr S., Jacobs R., Powell D., Nahmias A. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14;324(7):450–454. doi: 10.1056/NEJM199102143240704. [DOI] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES